Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C

European Journal of Immunology
E J Hindmarsh, R M Marks

Abstract

The vasculature is protected from complement activation by regulatory molecules expressed on endothelial cells. However, complement fixation also occurs on subendothelial extracellular matrix (ECM) in vitro, and is initiated simply by retraction or removal of overlying cells. To investigate mechanisms controlling vascular complement activation, we examined subendothelial ECM for the presence of complement regulatory proteins. Decay-accelerating factor (DAF) was found on both human umbilical vein endothelial cells (HUVEC) and in their ECM; in contrast, membrane cofactor protein was found only on cells. ECM and HUVEC DAF were distinguishable based on several properties. While HUVEC DAF is anchored to cell membranes by a phospholipase C-sensitive glycosylphosphatidylinositol linkage. DAF was removed from ECM only by proteolytic digestion. Cytokines (TNF-alpha, IL-1 beta, IL-4) increased HUVEC DAF expression, but had minimal effect on ECM DAF; in contrast, phorbol 12-myristate 13-acetate (PMA) and wheat germ agglutinin markedly increased DAF on both HUVEC and ECM. The effect of PMA was mediated by activation of protein kinase C. The complement regulatory potential of ECM DAF was assessed by evaluating the effect of DAF-neutralizing...Continue Reading

References

Jan 1, 1992·European Journal of Immunology·N JulenJ Ripoche
Apr 1, 1990·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·P D Yurchenco, J C Schittny
Jan 1, 1986·The Journal of Experimental Medicine·A S AschV Nussenzweig
Jan 1, 1989·Annual Review of Immunology·D M Lublin, J P Atkinson
Aug 1, 1989·The Journal of Clinical Investigation·T McNearneyJ P Atkinson
Dec 1, 1989·The Biochemical Journal·T Seya, J P Atkinson
Jul 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·T S LeeG L King
Aug 15, 1989·Biochemical and Biophysical Research Communications·J Heikkilä, K E Akerman
Aug 1, 1986·The Journal of Pathology·D R Abrahamson
Sep 9, 1985·Biochimica Et Biophysica Acta·C L Ashendel
Nov 1, 1987·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·P G de GrootJ J Sixma
Jul 1, 1993·Progress in Neurobiology·J MassouliéF M Vallette
Jun 1, 1993·Archives of Biochemistry and Biophysics·M M TaherV Natarajan
Dec 1, 1996·Protein Engineering·L Kuttner-KondoM Shoham

❮ Previous
Next ❯

Citations

Sep 15, 2011·PloS One·Anne Braunschweig, Mihály Józsi
Sep 23, 2006·Endothelium : Journal of Endothelial Cell Research·Konstantin Nizheradze
Feb 18, 2006·Cancer Immunology, Immunotherapy : CII·Ian SpendloveLindy G Durrant
Aug 24, 2001·International Journal of Cancer. Journal International Du Cancer·K JurianzM Kirschfink
Aug 24, 2013·International Journal of Oncology·Michael SafaeeAndrew T Parsa
Jul 13, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Anne KoppMihály Józsi
Jan 19, 2015·Arthritis Research & Therapy·Olga N KarpusJörg Hamann
Dec 18, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sarah E SartainJoel L Moake

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibodies: Complement Activation

The complement system can be activated by antigen-associated antibody. In the classical pathway of complement activation, C1q, C4b, and C3b are all able to bind to the Fc portion of IgG or IgM. Find the latest research on antibodies and complement activation here.